CLINICAL TRIAL: PHASE II TRIAL OF CTLA4IG IN THE TREATMENT OF LUPUS NEPHRITIS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本项目旨在测试在24周诱导方案中添加阿巴西普（包括环磷酰胺，随后依次使用硫唑嘌呤）是否可以比单独使用环磷酰胺和硫唑嘌呤治疗更频繁地诱导缓解。 次要目的是确定药物的安全性、免疫抑制药物停药后反应的持久性和部分反应率。 最后，第三个次要目的是确定与单独使用环磷酰胺的治疗相比，阿巴西普是否能够对疫苗接种产生更大的反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is designed to test whether addition of Abatacept to a 24-week induction protocol involving cyclophosphamide followed in turn by azathioprine can induce remission with greater frequency than treatment with cyclophosphamide and azathioprine alone. Secondary objectives are to determine the safety of the agent, the durability of the response when the immunosuppressive medications are stopped and the partial response rate. Finally, a third secondary objective is to ascertain whether the Abatacept enables greater response to vaccinations compared to therapy with cyclophosphamide alone.